• / Free eNewsletters & Magazine
  • / My Account
Home>Clinigen Group plc: Full Year Results

Clinigen Group plc: Full Year Results

Clinigen Group plc: Full Year Results


Clinigen Group plc: Full Year Results

Strong Performance with Adjusted EPS up 25%

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or ‘the Group’), the global pharmaceuticals and services group, has today published its full year results for the year ended 30 June 2017.


Year ended 30 June       2017       2016       Growth
        £m       £m        
Revenue       302.3       339.9       (11)%
Adjusted gross profit       122.8       100.7       22%
Adjusted EBITDA       65.1       53.7       21%
Cash generated from operations       54.7       49.4       11%
Reported earnings per share       3.3p       11.9p       (72)%
Adjusted earnings per share       41.8p       33.4p       25%
Dividend per share       5.0p       4.0p       25%
Net debt       35.0       68.1        

Note: The Group results on an adjusted basis exclude amortisation and non-underlying costs (see note 2 and 3 of this financial information). Adjusted EBITDA is also adjusted to include the Group’s share of EBITDA from its joint venture. Adjusted EBITDA and adjusted EPS metrics are now shown after share-based payments of £2.5m (2016: £2.3m). Prior year has been restated accordingly.


  • Adjusted gross profit up 22% - driven by organic growth, full year’s contribution from Link Healthcare (‘Link’) and currency benefits
  • Adjusted EPS up 25% to 41.8p (2016: 33.4p)
  • Strong cash flow performance with cash generated from operations of £54.7m (2016: £49.4m)
  • Net debt substantially decreased by £33.1m to £35.0m (2016: £68.1m)
  • Full year dividend increased 25% to 5.0p (2016: 4.0p)
  • Strong growth across all operations
  • Outstanding performance in Africa and Asia Pacific
  • Dexrazoxane portfolio revitalisation significantly enhanced by EC approval to update product information for Cardioxane, and launch of Totect in US
  • New simplified reporting structure comprising Clinical Trial Services (‘CTS’), Unlicensed Medicines and Commercial Medicines


  • Proposed acquisition of Quantum Pharma plc (‘Quantum’) for £150.3m announced on 13 September 2017 subject to Quantum’s shareholder approval

Shaun Chilton, Group Chief Executive Officer, said:

©2017 Morningstar Advisor. All right reserved.